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Abstract
Study Design: Systematic review and meta-analysis.
Objective: The objective of this study was to conduct a systematic review to assess the comparative effectiveness and safety of
high-dose methylprednisolone sodium succinate (MPSS) versus no pharmacological treatment in patients with traumatic spinal
cord injury (SCI).
Methods: A systematic search was performed in PubMed and the Cochrane Collaboration Library for literature published between
January 1956 and June 17, 2015. Included studies were critically appraised, and Grades of Recommendation Assessment, Development
and Evaluation methods were used to determine the overall quality of evidence for primary outcomes. Previous systematic reviews on
this topic were collated and evaluated using the Assessment of Multiple Systematic Reviews scoring system.
Results: The search yielded 723 citations, 13 of which satisfied inclusion criteria. Among these, 6 were primary research articles
and 7 were previous systematic reviews. Based on the included research articles, there was moderate evidence that the 24-hour
NASCIS II (National Acute Spinal Cord Injury Studies) MPSS regimen has no impact on long-term neurological recovery when all
postinjury time points are considered. However, there is also moderate evidence that subjects receiving the same MPSS regimen
within 8 hours of injury achieve an additional 3.2 points (95% confidence interval ¼ 0.10 to 6.33; P ¼ .04) of motor recovery
compared with patients receiving placebo or no treatment.
Conclusion: Although safe to administer, a 24-hour NASCIS II MPSS regimen, when all postinjury time points are considered, has
no impact on indices of long-term neurological recovery. When commenced within 8 hours of injury, however, a high-dose
24-hour regimen of MPSS confers a small positive benefit on long-term motor recovery and should be considered a treatment
option for patients with SCI.
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Introduction
Given its potent anti-inflammatory actions, methylprednisolone sodium succinate (MPSS) has a long history of use across
a wide spectrum of disease. Within the context of traumatic
spinal cord injury (SCI), preclinical animal studies have
demonstrated mixed results with regard to the neuroprotective
efficacy of MPSS.1-4 From the standpoint of clinical investigation, randomized trials, namely, the National Acute Spinal
Cord Injury Studies (NASCIS), investigating the potential efficacy and safety of MPSS, have formed the basis for the largest
therapeutic studies completed in the history of SCI research.
Although interpretation of, and reaction to, the results of these
studies have varied over time, their publication led to the widespread adoption of this therapy by clinicians throughout the
world. As evidence of this, in a 2006 survey study polling the
membership of the North American Spine Society, 86% of
respondents indicated that they would choose to administer
MPSS to SCI patients as per the recommendations of the NASCIS II and III studies; however, concern surrounding medicolegal reprisal for not administering MPSS was listed as the
major factor motivating decision making in a large faction of
these respondents.5
In spite of the extensive use of MPSS for SCI over the
past several decades, the appropriateness of this treatment
approach remains a contentious topic.6,7 Opponents of the
routine use of MPSS for acute SCI have highlighted concerns regarding the conduct of the NASCIS trials and the
reported results. These include the reliance on subgroup
analysis (particularly based on timing of MPSS initiation),
the small reported effect size for neurologic improvement,
and the potential for harmful and serious adverse events.8 In
order to quell the existing controversy, a number of attempts
have been made by several different groups to review the
existing evidence, with the aim of providing clinicians with
specific evidence-based recommendations related to this
treatment.9,10 In spite of such attempts, debate within the
clinical community continues, leaving the physician caring
for acute SCI patients in a precarious position where administering or not administering MPSS can be questioned and
challenged.
Based on this background, the purpose of this systematic
review was to address the following key questions (KQ): In
adult patients with acute complete or incomplete traumatic
SCI: (1) What is the efficacy and effectiveness of MPSS compared with no pharmacologic treatment? (2) What is the safety
profile of MPSS compared with no pharmacologic treatment?
(3) What is the evidence that MPSS has differential efficacy or
safety in subpopulations?

Materials and Methods
Electronic Literature Search
We conducted a systematic search in PubMed and the
Cochrane Collaboration Library for literature published
between January 1956 and June 17, 2015, on patients with
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acute traumatic SCI treated with MPSS. The search was
limited to human studies published in or translated to the
English language. Reference lists of key articles were also
systematically checked to identify additional eligible articles. We included studies that evaluated the efficacy and
safety of MPSS compared with no treatment or placebo in
patients 13 years with acute SCI (Table 1). With respect
to study design, all randomized controlled trials were
included. Severity of injury in SCI patients is a wellknown factor that is associated with outcome.11-14 Severity
of SCI may also influence the clinical decision of whether
to administer MPSS. Therefore, we included observational
studies that controlled for SCI severity, as measured by
baseline motor status and/or complete versus incomplete
injury. We excluded studies on patients with penetrating
injuries to the spinal cord; cord compression due to tumor,
hematoma, or degenerative disease; and no neurological
deficit following trauma. Furthermore, we excluded animal
studies, nonclinical studies, studies with a follow-up rate of
<50%, small studies with n<10 per treatment group, and
studies reporting nonclinical outcomes of efficacy or safety.
Two investigators (JRD, JRW) reviewed the full texts of
potential articles to obtain a final collection of relevant
studies.

Data Extraction
From the included articles, the following data was extracted:
study design, patient demographics, treatment details, study
inclusion/exclusion criteria, injury severity, follow-up duration, rates of follow-up for each treatment group, and outcomes assessed. We attempted to identify studies with
overlapping data and only reported the data from the most
complete study (largest sample size) in order to prevent
double counting.

Risk of Bias and Overall Strength of Body of Literature
Risk of bias was assessed by combining epidemiologic
principles with characteristics of study design. Risk of bias
was determined for each article using criteria set by The
Journal of Bone and Joint Surgery15 for therapeutic studies
and modified to delineate criteria associated with methodological quality and risk of bias based on recommendations made by the Agency for Healthcare Research and
Quality 16,17 (see Supplemental Digital Material for risk
of bias evaluation).
After individual article evaluation, the strength of the overall body of evidence with respect to each primary outcome was
determined based on precepts outlined by the Grades of Recommendation Assessment, Development and Evaluation
(GRADE) Working Group.18,19
The initial strength of the overall body of evidence was
considered “High” if the majority of the studies were randomized controlled trials and “Low” if the majority of the
studies were observational studies. Criteria for downgrading
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Table 1. Inclusion and Exclusion Criteria.
Study
Component
Participants

Intervention
Comparators
Outcomes

Study design

Publication

Inclusion

Exclusion

 Adults with traumatic acute spinal cord injury (complete or incomplete)

 MPSS
 Placebo
 Standard care without pharmacologic intervention
Efficacy/effectiveness
 Change in motor scores
 Change in sensation (light touch, pinprick)
Safety
 Complications, adverse events
 Death
 KQs 1, 2, 3: Comparative studies (RCTs and observational studies with
concurrent controls)
 Follow-up rate of at least 50%
 n  10 per group
 Observational comparative studies must control for severity of spinal
cord injury as evaluated by motor status at baseline and/or complete or
incomplete injury
 KQ 3: Subgroup analyses from comparative studies
 Studies published or translated into English in peer reviewed journals






Pediatric patients <13 years old
Pregnancy
Penetrating injuries to spinal cord
Cord compression due to tumor, hematoma
or degenerative disease (eg, CSM)
 Patients without neurological deficit
following trauma

 Nonclinical outcomes







Animal studies
Nonclinical studies
Follow-up rate of at <50%
n < 10 per group
No control for injury severity

 Abstracts, editorials, letters
 Duplicate publications of the same study that
do not report on different outcomes
 Single reports from multicenter trials
 White papers
 Narrative reviews
 Articles identified as preliminary reports
when results are published in later versions

Abbreviations: CSM, cervical spondylotic myelopathy; MPSS, methylprednisolone sodium succinate; KQ, key question; RCT, randomized controlled trial.

published evidence 1 or 2 levels included (1) serious risk of
bias, (2) inconsistency of results, (3) indirectness of evidence, (4) imprecision of the effect estimates (eg, wide
confidence intervals), or (5) non–a priori statement of subgroup analyses. Alternatively, the body of evidence could be
upgraded 1 or 2 levels based on the following factors: (1)
large magnitude of effect or (2) dose-response gradient. The
final overall strength of the body of literature expresses our
confidence that the effect size lies close to the true effect
and the extent to which it is believed to be stable based on
the adequacy of or the deficiencies in the body of evidence.
An overall strength of “High” means that we are very confident that the true effect lies close to that of the estimated
effect. A “Moderate” rating means that we are moderately
confident in the effect estimate; the true effect is likely to
be close to the estimated effect, but there is a possibility
that it is substantially different. An overall strength of
“Low” means that our confidence in the effect estimate is
limited; the true effect may be substantially different from
the estimate. Finally, a rating of “Very Low” means that we

have very little confidence in the effect estimate; the true
effect is likely to be substantially different than the estimated effect. In addition, this rating may be used if there
is no evidence or it is not possible to estimate an effect.

Data Analysis
Results were pooled when 2 or more studies presented the
same outcomes at similar time periods. We considered
the risk of bias when deciding whether to pool data between
the prospective cohort studies and randomized controlled
trials. Specifically, we pooled data from prospective cohort
studies if they had a low risk of bias and controlled for
potential confounding factors. For effectiveness outcomes,
pooled data was stratified by study design to demonstrate
the effect of adding nonrandomized results. To compare the
estimates of procedure effectiveness across studies using
continuous outcomes, weighted mean differences were computed with 95% confidence intervals (CIs). For safety outcomes, we calculated the risk difference (RD) and 95% CIs.
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We assumed a random-effect model using the MantelHaenszel method. Calculations and plots for effectiveness
outcomes were implemented in RevMan,20 while the complications plot was made with R (version 3.2.1).21
To explore the possibility of differential effectiveness,
we compared outcomes within subgroup stratum when
data was available. We tested the difference between
subgroups by calculating the I2 statistics. We displayed
the estimates visually with Forest plots to demonstrate
the differential effect. When the stratum-specific effect
measures and their CIs fall on opposite sides of the overall effect, this represents a differential effect.

Results
Study Selection
Our electronic and bibliography search yielded 723 citations. Of these, we excluded 693 based on information
available in the title or abstract. The full texts of 30 articles
were obtained and further investigated. After full text
review, we excluded 17 studies for the following reasons:
no control for baseline severity (n ¼ 13), no outcome of
interest (n ¼ 1), dexamethasone was evaluated instead of
MPSS (n ¼ 1), penetrating wounds (n ¼ 1), and population
size <10 (n ¼ 1). A list of excluded articles can be obtained
in the Supplemental Material.
Among the remaining 13 studies, 7 were systematic
reviews published between 2000 and 2014. The systematic
reviews differed with respect to inclusion criteria, methodology, and conclusions (Table 2). The quality of the systematic reviews ranged from 2/11 (low quality) to 9/11
(high quality) as assessed by the Assessment of Multiple
Systematic Reviews (AMSTAR) evaluation tool (see Supplemental Material for details). All included the NASCIS II
study. Of the remaining 6 studies that met our inclusion
criteria, four were randomized controlled trials and 2 were
prospective cohort studies (Figure 1).

Characteristics of Included Studies (Table 3)
Three randomized controlled trials (4 publications)22-25 and
1 prospective cohort study26 evaluated the efficacy and
safety of MPSS, while 3 additional studies (2 randomized
controlled trials and 1 prospective cohort study) provided
further evidence on its safety. 27-29 In 1990 and 1992,
Bracken et al published a double-blind randomized controlled trial, also known as NASCIS II, with 6 weeks,
6 months, and 1 year of follow-up. They randomized 487
patients across 3 treatment arms: (1) MPSS bolus dose of
30 mg/kg at hospital admission, followed by an infusion at
5.4 mg/kg/h for the following 23 hours; (2) naloxone; or
(3) placebo. Naloxone and its placebo were provided in
100-ampule sets of 2-mL parabens-free ampules and prepared at a concentration of 25.0 mg/mL. This was followed
by a third and final NASCIS study that compared 24-hour
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versus 48-hour MPSS infusion using the same dose as
NASCIS II, as well as to a 48-hour infusion of the
putative neuroprotective drug Tirilazad. All patients were
randomized to receive treatment within 8 hours of injury,
with the analysis stratified according to whether
treatment was initiated before or after 3 hours of injury
(Table 4).29
Otani et al24 published an article in Japanese that randomized 117 patients to a MPSS group (n ¼ 70) or a standard
care group (n ¼ 47). Treatment with other drugs, concomitant
procedures (such as decompression of the spinal cord or reduction of a dislocation or a fracture), and rehabilitation were
performed at the discretion of the attending physician. Neither
the patients nor the outcome assessors were blinded to the
treatment. Seventy-four percent of patients attended the
6-month follow-up visit.
Matsumoto et al27 compared the incidence of complications
during the first 2 months after injury in 46 patients with cervical SCI. Patients were randomized to receive MPSS using the
NASCIS II protocol or a placebo, though the methods of random generation and concealment were not clear. All patients
received treatment within 8 hours. At baseline, the MPSS group
presented with more severe injuries: 39% in the MPSS group
versus 26% in the placebo group with Frankel grade A, and 4%
in the MPSS group versus 30% in the placebo group with
Frankel grade D.
Wilson et al28 assessed inpatient complications after traumatic cervical SCI from the Surgical Timing in Acute Spinal
Cord Injury Study data registry. Patient information was collected on adults with cervical SCIs who were enrolled at
6 North American centers over a 7-year period. This study
included patients who underwent a standardized American
Spinal Injury Association neurological examination within
24 hours of injury and had follow-up information at the index
hospital discharge. Decisions surrounding the administration
of MPSS were made at the discretion of the spinal surgeon and
the treating team.
Evaniew et al performed a prospective multicenter study
using the Rick Hansen Spinal Cord Injury Registry to evaluate the impact of MPSS on motor recovery at the end of
inpatient rehabilitation or discharge to the community from
acute care.26 Forty-four patients received MPSS within 8
hours of acute injury following the NASCIS II regiment.
Patients treated with an additional 24 hours of MPSS were
also included. The control group consisted of 44 subjects
who did not receive MPSS and was selected using propensity score matching. Despite this matching, those who
received MPSS had a longer time from injury to first
assessment of motor scores (median 72 vs 56 hours).
Motor function scores (upper extremity, lower extremity,
and total) were determined using the International Standards for Neurologic Classification of Spinal Cord Injury.
Safety was determined by collecting rates of in-hospital
mortality, urinary tract infections, pneumonia, ulcers, deep
vein thrombosis or pulmonary embolism, surgical site
infections, and sepsis using International Classification of
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Literature Search
Dates
Purpose

Hurlbert
(2001)36

NR

To review available literature and
formulate evidence-based
recommendations for the use of
MPSS in acute SCI

Short (2000)35 1966 to December To summarize the evidence evaluating
1999
the effect of high-dose MPSS on
neurological improvement following
acute SCI

Assessment
(Year)
Inclusion:
 High-dose MPSS
or equivalent
dexamethasone
given 12 hours of
SCI
 Outcome
measures
reported
separately for
steroid and nonsteroid groups
Exclusion:
 Questionable
study validity
NR

Inclusion Criteria

Follow-up
Range

 5 RCTs, 3
retrospective
cohorts, 1 casecontrol
(N ¼ 2455)

AMSTAR
Scorec

(continued)

2/11; low
quality

Efficacy: The evidence produced 4/11; medium
quality
by this systematic review does
not support the use of highdose MPSS in acute SCI to
improve neurological recovery.
Safety: A deleterious effect on
early mortality and morbidity
cannot be excluded by this
evidence.
Economic: Not addressed

Primary Conclusions

2 months to Efficacy: All studies failed to
30 months
demonstrate improvement
from steroid administration in
any of the a priori hypotheses
tested; MPSS cannot be
recommended for routine use
in acute nonpenetrating SCI.
Safety: Prolonged administration
of high-dose steroids (48
hours) may be harmful.
Economic: Not addressed

24 hours to
 3 RCTs,
6 nonrandomized
4þ years
studies
(N ¼ 1018)b

Evidence Base
Availablea,b

Table 2. Overview of Previous Systematic Reviews of MPSS vs Control (Placebo or no MPSS) in the Treatment of Acute Spinal Cord Injury.
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MEDLINE January
1, 1966, to April
2001
CINAHL 19822001
HealthSTAR 19902000

Hugenholtz
(2002)37

Sayer (2006)38 NR

Literature Search
Dates

Assessment
(Year)

Table 2. (continued)
Inclusion Criteria

To summarize the evidence evaluating
the use of MPSS in acute SCI

NR

Inclusion:
To address controversy surrounding
the use of MPSS infusion after acute
 Acute SCI
SCI
 MPSS
 Clinical trials
(randomized or
nonrandomized)
Exclusion:
 Articles confined
to a pediatric
population
 Gunshot or open
SCI
 Nontraumatic SCI
 Animal
experiments
 Nonsteriod
therapy
 Articles that did
not address clinical
data

Purpose

 3 RCTs, 6
nonrandomized
studies
(N ¼ 2173)

 3 RCTs, 5
nonrandomized
studies, 1 review
(N ¼ 3169)

Evidence Base
Availablea,b

6 weeks to
2þ years

6 weeks to
1 year

Follow-up
Range

AMSTAR
Scorec

(continued)

4/11; medium
Efficacy: There is insufficient
quality
evidence to support the use of
high-dose MPSS within 8 hours
following an acute closed SCI as
a treatment standard or as a
guideline for treatment. MPSS,
prescribed as a bolus IV infusion
of 30 mg/kg of body weight over
15 minutes within 8 hours of
closed SCI, followed 45 minutes
later by an infusion of 5.4 mg/kg
of body weight per hour for 23
hours, is a treatment option
with weak clinical evidence
(Level I to II-1). There is
insufficient evidence to support
extending MPSS infusion
beyond 23 hours if chosen as a
treatment option.
Safety: In well-designed studies,
there are no statistically
significant complications to
MPSS therapy; there are,
however, trends to increased
sepsis and hyperglycemia.
Economic: The NASCIS II and III
protocols would cost $322.02
and $579.32, respectively, per
patient. Nursing time and
equipment costs are not
included.
2/11; low
Efficacy: There is insufficient
quality
evidence to support the use of
MPSS as a standard treatment in
acute SCI.
Safety: MPSS use is associated with
increased risk of infections.
Economic: Not addressed

Primary Conclusions
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1966-2011

To build upon a medical evidence-based Inclusion: NR
guideline on the use of MPSS and GM- Exclusion:
1 Ganglioside previously published by  Non-English or
the AANS and CNS
nonhuman
 Case reports
 Pharmacokinetic
reports
 General reviews
 Editorials
 Critiques
 Manuscripts
without original
data

 6 RCTs (9
reports), 14
nonrandomized
studies
(N ¼ 14 138)

Primary Conclusions

AMSTAR
Scorec

2 weeks to
1 year

9/11; high
Efficacy: MPSS enhances
quality
neurologic recovery if therapy
is started within 8 hours of
injury by using an initial bolus of
30 mg/kg by IV for 15 minutes,
followed 45 minutes later by a
continuous infusion of 5.4 mg/
kg/h for 24 hours.
Safety: Not addressed
Economic: Not addressed
Efficacy: There is no Class I or II 2/11; low
quality
medical evidence suggesting any
beneficial effect of MPSS in an
acute SCI population; however,
Class III medical evidence has
supported the neuroprotective
effect of MPSS.
Safety: Class I, II, and III evidence
suggests that high-dose
steroids are associated with
harmful side effects including
death.
Economic: Not addressed

6 months to Efficacy: The results do not suggest 6/11; medium
quality
1 year
clinical benefits of MPSS due to
only modest differences
between treatment strategies.
Safety: The use of MPSS is
associated with an increased
risk of pulmonary
complications and
gastrointestinal bleeding in
patients aged approximately 60
years.
Economic: Not addressed

Follow-up
Range

2 weeks to
 3 RCTs
1 year
(6 reports), 5 nonRCTs (N ¼ 1660)

 2 RCTs (3
reports)
(N ¼ 533)

Evidence Base
Availablea,b

Abbreviations: AANS, American Association of Neurological Surgeons; CINAHL, Current Index to Nursing and Allied Health Literature; CNS, Congress of Neurological Surgeons; EMBASE, Excerpta Medical Database;
HealthSTAR, Health Services Technology, Administration, and Research; LILACS, Literatura Latino Americana em Ciências da Saúde; MEDLINE, Medical Literature Analysis and Retrieval System Online; MPSS,
methylprednisolone sodium succinate; N/A, not available; NASCIS, National Acute Spinal Cord Injury Study; NR, not reported; RCT, randomized controlled trial; SCI, spinal cord injury.
a
The NASCIS RCTs were published as multiple reports with different follow-up times.
b
Short (2000): Included 2 studies with penetrating spinal cord injury (gunshot).
c
Assessment of Multiple Systematic Reviews evaluation tool: high quality, 8 to 11; medium quality, 4 to 7; low quality, 0 to 3.

Hurlbert
(2013)9

Bracken
(2012)30

MEDLINE, LILACS, To review RCTs evaluating the use of Inclusion:
and EMBASE
MPSS compared with placebo for SCI  Randomized trials
of patients with
traumatic SCI
Exclusion:
 Studies examining
spinal trauma
without SCI
 Studies examining
victims of whiplash
injury without
neurological
damage
Through August
To assess the effects of steroids in
Inclusion:
2011
patients with acute SCI
RCTs including
patients with:
 Acute spinal cord
injury
 Whiplash, lumbar
disc disease
 Steroid treatment
Exclusion: NR

Inclusion Criteria

Botelho
(2009)39

Purpose

Literature Search
Dates

Assessment
(Year)

Table 2. (continued)

Fehlings et al
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MPSS, there was a significantly higher incidence of severe
pneumonia (P ¼ .02) in the 48-hour group. Additionally, there
was an increased incidence of severe sepsis in the 48-hour
group, though the difference between the 24-hour and
48-hour groups for this outcome was within the limits of
chance (P ¼ .07).29

What Is the Evidence That MPSS Has Differential
Efficacy or Safety in Subpopulations?

Figure 1. Literature search.

Diseases, Tenth Edition, codes from the Canadian Institute
for Health Information’s Discharge Abstract Database.

What Is the Efficacy of Methylprednisolone Sodium
Succinate Compared With No Pharmacologic
Treatment?
Three randomized trials22-25 and 1 prospective observational
study evaluated the efficacy of MPSS compared with no pharmacologic treatment.26 Based on the randomized controlled
trials, there was no effect of MPSS on motor function at
6 weeks, 6 months, or 12 months (Figure 2). Likewise, in the
observational study, there was no difference between those
who did and did not receive MPSS in terms of total motor
recovery (13.7 vs 14.1, respectively; P ¼ .43), upper extremity
motor recovery (7.3 vs 6.4; P ¼ .38), or lower extremity motor
recovery (6.5 vs 7.7; P ¼ .40). Pinprick sensation was significantly improved at 6 months in one randomized controlled
trial (mean difference ¼ 3.37; 95% CI ¼ 0.75 to 5.99)23 but
not in 2 other trials at 12 months (Figure 3).23,25 Similar results
were seen for light touch (Figure 4).

What Is the Safety Profile of MPSS Compared With No
Pharmacologic Treatment?
There was no statistical difference between groups in the
pooled risk of death, wound infection, gastrointestinal hemorrhage, sepsis, pulmonary embolism, urinary tract infection,
pneumonia, or decubiti. One prospective nonrandomized study
evaluated the risk of one or more complications and found a
lower risk in those receiving MPSS, after controlling for severity of injury and other baseline differences (risk difference ¼
12.6%, 95% CI ¼ 3.1% to 22.1%; Figure 5). In one randomized
controlled trial comparing 24-hour versus 48-hour infusion of

In the study by Bracken et al, there was a differential effect of
MPSS on motor recovery compared with controls depending on
the timing of MPSS administration. Patients receiving MPSS
within 8 hours had a mean 4.8- and 5.2-point improvement in
motor scores at 6 and 12 months follow-up compared with a
mean 3.9- and 5.8-point deterioration when administered after
8 hours (Figure 6). There was no evidence of a differential
effect of the timing of MPSS administration on pinprick or
light touch (Figures 7 and 8).
Two additional randomized controlled trials and one
prospective observational study compared MPSS to a control in patients receiving treatment within 8 hours. Based
on the randomized controlled trials, pooled results at final
follow-up (6 or 12 months) demonstrated a modest
improvement of 3.88 (95% CI ¼ 0.50 to 7.27; P ¼ .02)
in mean motor scores in the MPSS group compared with
the control group. When adding the results of the prospective cohort study (median follow-up of 127 and 117 days
in the MPSS and control groups, respectively), this mean
difference decreased to 3.21 (95% CI ¼ 0.10 to 6.33; P ¼
.04; Figure 9).

Evidence Summary (Table 5)
There is moderate evidence that MPSS (compared with no
treatment or placebo) administered according to the dose
and duration of the NASCIS II protocol confers no benefit
in motor recovery, pinprick, or light touch when initiated at
indiscriminate time periods following acute SCI. However,
there is moderate evidence of a small benefit in motor
recovery when MPSS is administered within 8 hours of
injury compared with no treatment. There is no difference
between groups in the pooled risk of death, wound infection, gastrointestinal hemorrhage, sepsis, pulmonary embolism, urinary tract infection, pneumonia, or decubiti. The
evidence for safety is moderate. There may be a higher
incidence of severe pneumonia and increased incidence of
severe sepsis when the duration of infusion increases from
24 hours to 48 hours.

Discussion
The primary goal of this systematic review was to determine the efficacy and safety of MPSS compared with no
treatment or placebo. While the majority of primary
research articles emanated from prospective randomized
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N ¼ 487
MPSS:
Male: 86.4%
Age:
13-29: 55.5%
30-44: 27.2%
45: 17.3%
Naloxone:
Male: 80.5%
Age:
13-29: 63.6%
30-44: 18.7%
45: 17.6%
Placebo:
Male: 84.8%
Age:
13-29: 52.6%
30-44: 28.7%
45: 18.8%

N ¼ 117
Male: 76.1%
Age:
40-49: 14.5%
50-59: 26.5%
60-69: 18.8%

Bracken (1990/
92)22,23
RCT
Low

Otani
(1994)b,24
RCT
Moderately
high

Inclusion Criteria

Inclusion:
 SCI
 Randomized
12 hours of injury
 Consent
Exclusion:
 Nerve root
involvement
 Cauda equina alone
 Gunshot wounds
 Life-threatening
morbidity
 Pregnancy
 Narcotic addiction
 Other steroid usage
 <13 years of age
 Receiving 100 mg MPSS
or naloxone before
admission
 Difficulty with
following-up
MPSS: n ¼ 70
Inclusion:
IV bolus dose of 30 mg/kg of body
 SCI with motor/
weight over a 15-minute period
sensory loss
followed by a 45-minute pause
 Treated 8 hours after
and then an infusion at 5.4 mg/kg/h
injury
for 23 hours
 Consent
Control: n ¼ 47
 16-65 years of age
Drug therapies without a
 Available for 6 month
corticosteroid and surgical
follow-up
treatment
Exclusion:
Patients with:
 Spinal root and/or
cauda equina lesions
only
 Serious comorbidity
 100 mg MPSS between
injury and treatment
initiation
 Other steroid use
 Congenital or previous
spinal cord illness/
injury
 Pregnant, nursing, or
suspect pregnancy
 Hypersensitivity to
corticosteroids
 Physician decision

MPSS: n ¼ 162
IV bolus dose of 30 mg/kg body
weight over a 15-minute period
followed by a 45-minute pause,
then infusion at 5.4 mg/kg/h for
23 hours
Naloxone: n ¼ 154
IV bolus dose of 5.4 mg/kg body
weight over a 15-minute period
followed by a 45-minute pause,
then infusion at 4.0 mg/kg/h for
23 hours
Placebo: n ¼ 171
IV bolus dose and then an infusion
given—no other info given as to
the time or amount

Author (Year),
Design, Risk of Sample and
Bias
Characteristics Treatment

Table 3. Study Characteristics*.

Follow-up
Time (%)
Funding

NR

(continued)

Motor score:
6 weeks: 477/ National Institute of Neurological
487
Disorders and Stroke (Grant NS
0-5 (no contraction to
(97.9%)
15078)
normal function) for
6 months:
14 muscles—range
470/487
from 0 to 70
(96.5%)
Response to pinprick and
1 year: 427/
light touch:
487
1-3 (absent, dysfunction,
(87.7%)a
or normal) in 29
segments—range 29
to 87

Outcome Measures

Frankel Classification:
6 months:
 Quadriplegic:
39/117 (33.3%)  A ¼ complete
117/158
(74.1%)
lesion; B ¼ sensory
 Paraplegic: 25/
117 (21.4%)
only; C ¼ motor
useless; D ¼ motor
 Quadriparetic:
20/117 (17.1%)
useful; E ¼ recovery
 Paraparetic: 5/
 Changes in
117 (4.2%)
classification were
compared from
 Normal: 28/
117 (23.9%)
baseline to each
time point

 Quadriplegic:
228/484
(47.1%)
 Paraplegic:
159/484
(32.9%)
 Quadriparetic:
49/484 (10.1%)
 Paraparetic:
12/484 (2.5%)
 Normal: 36/
484 (7.4%)

Severity (on
Admission)

125S

Pointillart
(2000);
Petitjean
(1998)e,25
RCT
Low

Bracken (19978)29,40
RCT
Low

N ¼ 499
MPSS 24 hours:
Male: 85.5%
Age:
14-29: 42.3%
30-44: 29.5%
45: 28.3%
TM 48 hours:
Male: 86.8%
Age:
14-29: 47.4%
30-44: 31.2%
45: 21.6%
MPSS 48 hours:
Male: 81.9%
Age:
14-29: 45.9%
30-44: 32.5%
45: 21.6%
N ¼ 106
% Male: NR
MPSS:
Age: 32
(25-44)
NP:
Age: 32
(26-47)
MPSS and NP:
Age: 28
(20-39)
Placebo:
Age: 28
(25-42)f
Inclusion:
 SCI
 Consent
 14 years old
Exclusion:
Patients:
 Pregnant
 Illegal immigrants
 Indicted criminals
 Serious comorbidity
 More than 109 kg
(242 lb)
 Gunshot wounds
 Previous spinal injury
 Previous MPSS
treatment

Inclusion Criteria

MPSS: n ¼ 27
Inclusion:
IV bolus dose of 30 mg/kg over
 15-65 years
1 hour, then 5.4 mg/kg/h for
 Consent
23 hours
 Hospitalized 8 hours
NP: n ¼ 27
of injury
NP dose of 0.15 mg/kg/h for 2 hours, Exclusion:
then 0.03 mg/kg/h for 7 days
 Nerve-root
MPSS and NP:
involvement
MPSS and NP at the same doses
 Cauda equina
Placebo: n ¼ 25
syndrome
Neither medication received
 Open spinal lesions
 Pregnancy
 Multiple trauma
 Head injury with
Glasgow score <13
 Pulmonary contusion
 Persistent
hemodynamic
instability
 MAP <60 mm Hg
 Previous
corticosteroids or
calcium channel
blockers
 History of diabetes
mellitus
 Stomach ulcer
 Liver failure
 Cardiovascular
disorders

MPSS 24 hours: n ¼ 166
IV bolus dose of 30 mg/kg body
weight followed by 5.4 mg/kg/h
for 24 hours, then placebo given
every hour for next 24 hours
TM 48 hours: n ¼ 167
IV bolus dose of 30 mg/kg body
weight followed by 2.5 mg/kg
every 6 hours for 48 hours
MPSS 48 hours: n ¼ 166
IV bolus dose of 30 mg/kg body
weight followed by 5.4 mg/kg/h
for 48 hours

Author (Year),
Design, Risk of Sample and
Bias
Characteristics Treatment

Table 3. (continued)
Follow-up
Time (%)
Funding

(continued)

Motor score:
6 weeks: 465/ National Institute of Neurological
0-5 (no contraction to
Disorders and Stroke (Grant NS499
normal function) for
15078)
(93.2%)
14 muscles—range
6 months:
from 0 to 70
444/499
Response to pinprick and
(89.0%)
light touch:
1 year: 431/
1-3 (absent, dysfunction
499
or normal) in 29
(86.4%)d
segments—range 29
to 87
Functional Independence
Measure (FIM):
18-126 (need for
assistance in all areas
to complete
independence)

Outcome Measures

1 year: 100/ NR
 Paraplegia: 48/ ASIA motor, pinprick
106 (45.3%)
sensation, and pain
106
scores:
(94.3%)
 Tetraplegia:
58/106 (54.7%) Neurological
5 patients lost
examination at
to death
admission and 1 year
later

 Quadriplegic:
*35.2%
 Paraplegic:
*30.9%
 Quadriparetic:
*13.4%
 Paraparetic:
*4.0%
 Normal:
*16.5%c

Severity (on
Admission)

126S

Wilson
(2012)28
STASCIS trial,
prospective
cohort
Moderately
high

Matsumoto
(2001)27
RCT
Moderately
high

Inclusion Criteria

Severity (on
Admission)
Outcome Measures

Follow-up
Time (%)
Funding

(continued)

2 months, 46/ NR
MPSS: n ¼ 23
Inclusion:
Frankel grade
Frankel Classification:
46 (100%)
IV bolus dose of 30 mg/kg of body
 Cervical SCI, 1993 A: 15/46
 A ¼ complete
weight over a 15-minute period
1999
(32.6%)
lesion; B ¼ sensory
followed by a 45-minute pause
only; C ¼ motor
 Randomized 8 hours
 B: 16/46
and then an infusion at
of injury
(34.8%)
useless; D ¼ motor
5.4 mg/kg/h for 23 hours
useful; E ¼ recovery
 Consent
 C: 7/46 (15.2%)
Placebo: n ¼ 23
Exclusion:
 D: 8/46
 Changes in
15-minute bolus of 30 mg/kg
(17.4%)
classification were
 Involvement of 1
followed by a 45-minute pause,
nerve root
compared from
and then a 23-hour maintenance
baseline to each
 Gunshot wounds
time point
infusion of 5.4 mg/kg
 Life-threatening
morbidity
 Pregnancy
 Narcotic addiction
 Other steroid usage
 Operative treatment
 MPSS or equivalent
before admission
 Difficult follow-up
 Ankylosing spondylitis
N ¼ 411
MPSS:
Christopher and Dana Reeve
Inclusion:
AIS Grade:e
 Complications: 160/ NR
Mean age: 44.4 233/411 (56.7%) 24-hour, low-dose
411 (38.9%)
Foundation, Cervical Spine Research
 A: 144/411
 Patients with SCI
(35.0%)
+17.0
MPSS regimen from the NASCIS
Society, AANS/CNS Section on
 16 years of age
Male: 308/411
II study
Disorders of the Spine and Peripheral
 B: 66/411
 Presented to one of
(16.1%)
(74.9%)
Nerves, and Rick Hansen Institute
the participating
institutions
 C: 86/411
(20.9%)
 AIS Grade of A-D
 A cervical neurological  D: 115/411
(28.0%)
level of injury (C2-T1)
 Radiographic evidence ISS Score:
of spinal cord
 12.5 + 10.5
compression
 Documented
neurological
examination <24 hours
of injury and follow-up
available at acute care
discharge

N ¼ 46
Male: 91.3%
Mean age
(range):
60.6 (20-84)
MPSS:
Male: 91.3%
Mean age
(range):
60.9 (41-84)
Placebo:
Male: 91.3%
Mean age
(range):
60.4 (20-84)

Author (Year),
Design, Risk of Sample and
Bias
Characteristics Treatment

Table 3. (continued)
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N ¼ 88
MPSS:
Male: 81.8%
Mean age: 45.4
+ 16.2
No MPSS:
Male: 93.2%
Mean age: 45.5
+ 16.6

MPSS: n ¼ 44
Inclusion:
MPSS regimen from the NASCIS II
 Traumatic SCI
study given within 8 hours of
 18 years of age
injury and administered for 24 or Exclusion:
48 hours
 SCI due to infection,
Control: n ¼ 44
neoplasm, iatrogenic
Propensity matched SCI patients
or vascular causes
with no MPSS administration

Inclusion Criteria
AIS Grade:
 A: 40/88
(45.5%)
 B: 66/411
(12.51%)
 C: 86/411
(15.9%)
 D: 115/411
(26.1%)

Severity (on
Admission)
Motor score:
International Standards
for Neurologic
Classification of
Spinal Cord Injury
(ISNCSCI)
In-hospital complications

Outcome Measures

Funding

Median
Rick Hansen Institute, Health Canada,
number of
Western Economic Diversification
days: 127
Canada, and the Governments of
(MPSS) and
Alberta, British Columbia, Manitoba,
117 (no
and Ontario
MPSS)
44/46 (95.7%)

Follow-up
Time (%)

Abbreviations: AANS, American Association of Neurological Surgeons; ASIA, American Spinal Injury Association; CNS, Congress of Neurological Surgeons; IV, intravenous; MAP, mean arterial pressure; MPSS,
methylprednisolone sodium succinate; NP, nimodipine; NR, not reported; RCT, randomized controlled trial; RHSCIR, Rick Hansen Spinal Cord Injury Registry; SCI, spinal cord injury; TM, tirilazad mesylate.
*Bracken studies are reported as a primary report and then a follow-up report 1 year later; 6-week and 6-month follow-up information are based on primary reports; 1-year follow-up is based on the follow-up report.
a
Bracken (1990/1992): Measured in 161 patients in the methylprednisolone group, 153 in the naloxone group, and 170 in the placebo group.
b
English translation of an article originally published in Japanese.
c
Bracken (1997/98): Motor function percentages are averaged from percentages of each treatment group in Table 2.
d
Bracken (1984/5): 330 refers to number of patients randomized, 24 patients were excluded from analysis after randomization, n ¼ 306.
e
Petitjean 1998 was published in a French journal, and Pointillart 2000 was published in an English journal.
f
Petitjean 1998: Age values expressed as averages with 25th and 75th percentiles in parentheses.

Evanview
(2015)26
Prospective
cohort
RHSCIR
Moderately
low

Author (Year),
Design, Risk of Sample and
Bias
Characteristics Treatment

Table 3. (continued)
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6 months
2 RCTs (N ¼
414)23,24
12 months
2 RCTs (N ¼
335)22,25
6 months
1 RCTs (N ¼
296)23
12 months
2 RCTs (N ¼
334)22,25
6 months
1 RCTs (N ¼
294) 23
12 months
2 RCTs (N ¼
334) 22,25
No serious
risk of
bias

No serious
risk of
bias

No serious
risk of
bias

No. of Studies;
Sample Size
Risk of Bias
Indirectness

Imprecision

PE

Sepsis

GI hemorrhage

Wound
infection

Death

3 RCTs (N ¼ No serious
530)22-24,27
risk of
bias
1 non RCT
(N ¼ 88)26
3 RCTs (N ¼ No serious
434)22,23,25,27
risk of
bias
1 Non-RCT
(N ¼ 88)26
3 RCTs (N ¼ No serious
434)22,23,25,27
risk of
bias
3 RCTs (N ¼ No serious
434)22,23,25,27
risk of
bias
1 Non-RCT
(N ¼ 88)26
2 RCTs (N ¼ No serious
238)22,23,25
risk of
bias
1 Non-RCT
(N ¼ 88)26

Publication
Bias

Overall
Quality
of Evidence

No serious
No serious
Serious risk of Undetected Moderate
inconsistency
indirectness
imprecision

No serious
No serious
Serious risk of Undetected Moderate
inconsistency
indirectness
imprecision

No serious
No serious
Serious risk of Undetected Moderate
inconsistency
indirectness
imprecision

Inconsistency

Control %

6.07% (13/214)

5.81% (15/258)

8.09% (19/235) 4.592% (111/241) 2.94 (0.15, 6.03); P ¼ .06

No serious
No serious
Serious risk of Undetected Moderate
inconsistency
indirectness
imprecision

No serious
No serious
Serious risk of Undetected Moderate
inconsistency
indirectness
imprecision

4.92% (13/264)

2.27% (5/20)

(continued)

0.74 (2.88, 4.35); P ¼ .69

4.51 (1.92, 10.94); P ¼ 17

0.98 (1.70, 3.66); P ¼ .47

No serious
No serious
Serious risk of Undetected Moderate
inconsistency
indirectness
imprecision

2.27% (6/264)

4.26% (11/258)

1.51 (4.13, 1.12); P ¼ .26

No serious
No serious
Serious risk of Undetected Moderate
inconsistency
indirectness
imprecision

4.87% (15/308)

2.58% (8/310)

MPSS %

6 months
2.88 (0.10, 5.66); P ¼ .04
12 months
0.74 (2.12, 3.61); P ¼ .61

6 months
3.37 (0.75, 5.99); P ¼ .01
12 months
0.18 (2.66, 3.02); P ¼ .90

6 months
1.19 (2.34, 4.72); P ¼ .51
12 months
1.17 (4.80, 2.47); P ¼ .53

Mean Difference
(95% CI, P Value)

Effect Size

No serious
No serious
Serious risk of Undetected Moderate
inconsistency
indirectness
imprecision

KQ2. What is the safety profile of MPSS compared with no pharmacologic treatment?

Light touch

Pinprick

Motor scores

Outcome

KQ1. What is the efficacy and effectiveness of MPSS compared with no pharmacologic treatment?

Table 4. Evidence Summary Table.
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No serious
risk of
bias

25.50% (51/200) 21.33% (45/211)

15.7% (35/223) 14.96% (35/234)

33.48% (78/233) 46.07% (82/178)

Undetected Moderate

Undetected Moderate

Undetected Very low

No serious
No serious
Serious risk of Undetected Moderate
inconsistency
indirectness
imprecision

35.27% (91/258) 34.47% (1/264)

Undetected Moderate

Abbreviations: CI, confidence interval; GI, gastrointestinal; MPSS, methylprednisolone sodium succinate; PE, pulmonary embolism; RCT, randomized controlled trial.

MPSS administered within 8 hours
Motor scores
Final follow-up
(6-12
months)
3 RCTs (N ¼
300)22,24,25
Median time 3
months
1 Non-RCT
(N ¼ 88)26

Urinary
infection

No serious
Serious risk of
3 RCTs (N ¼ No serious No serious
inconsistency
indirectness
imprecision
risk of
434)22,23,25,27
bias
1 Non-RCT
(N ¼ 88)
Pneumonia
1 RCT (N ¼
No serious
Serious risk of
No serious No serious
156)
inconsistency
indirectness
imprecision
risk of
1 Non-RCT
bias
(N ¼ 88)26
No serious
Serious risk of
Decubitis
2 RCTs (N ¼ No serious No serious
inconsistency
indirectness
imprecision
238)22,23,27
risk of
bias
1 Non-RCT
(N ¼ 88)26
No serious
Serious risk of
One or more
1 NonNo serious No serious
inconsistency
indirectness
imprecision
complications
RCT28
risk of
bias
(N ¼ 411)
KQ3. What is the evidence that MPSS has differential efficacy or safety in subpopulations?

Table 4. (continued)

RCTs: 3.88 (0.50, 7.27); P ¼
.02
RCTs þ Prospective cohort:
3.21 (0.10, 6.33); P ¼ .04

12.59 (22.10, 3.09); P ¼
.009

20.99 (6.01, 7.98); P ¼ .78

4.69 (3.19, 12.57); P ¼ .24

1.73 (5.04, 8.49); P ¼ .62
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Figure 2. Motor scores, all patients.
*Prospective cohort study with median follow-up of 127 and 117 days in the MPSS and control groups, respectively.

Figure 3. Pinprick, all patients.

controlled trials, 2 observational studies also met eligibility criteria and were included in this review. With respect
to the overall impact of MPSS, there were no differences
in motor and sensory neurological recovery between
patients treated with MPSS and those receiving placebo
or no treatment. The overall strength of this conclusion
was “Moderate,” meaning that, based on assessment of
risk of bias and the strength of the overall body of

evidence, we are moderately confident that the calculated
effect estimate reflects the true estimate.
From the perspective of safety, when considering the NASCIS II 24-hour MPSS regimen, there was a trend toward
reduced mortality in patients receiving MPSS as compared to
no treatment. Similarly, with respect to complications, there
were no significant differences between patients who
received the 24-hour NASCIS II regimen of MPSS and

Fehlings et al
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Figure 4. Light touch, all patients.

those who did not. There were, however, trends toward an
increased incidence of pulmonary embolism and gastrointestinal hemorrhage in patients treated with MPSS; the relative severity of these events and their impact on recovery
and mortality is unknown. In general, when considering the
24-hour NASCIS II MPSS regimen, we can conclude with a
moderate degree of confidence that there are no significant
differences in rates of mortality or other complication
between treated and untreated patients. Although not the
primary focus of this review, compared to patients receiving
the 24-hour NASCIS II regimen, patients treated with the
48-hour NASCIS III regimen experienced higher rates of
severe sepsis (P ¼ .02) and pneumonia (P ¼ .07); this may
represent a valid argument against the administration of the
48-hour regimen to SCI patients (Table 5).
We also evaluated outcomes based on time to drug
administration and specifically examined the impact of
MPSS within the first 8 hours of injury. The importance
of this time window was established based on a subgroup
analysis from the NASCIS II study: the authors reported a
significantly larger improvement in long-term motor score
recovery (an additional 4 points of improvement) in patients
receiving the 24-hour MPSS compared to those receiving
placebo. Critics of the NASCIS II study have commented
on the potential bias associated with this “post hoc” retrospective subanalysis. In reality, however, the authors of the
NASCIS II study indicate that an a priori hypothesis was
made that the effects of MPSS are influenced by how
quickly treatment is administered postinjury; that said, the
specific method for selecting the 8-hour cutoff was not fully
described in the primary manuscript text. However, in subsequent articles, rationale for selecting the 8-hour cutoff is
further explained. In a commentary piece published in 2000
by Bracken, he indicates,

It is important that major analytic stratifications be part of the
original proposal and such was the case in NASCIS 2, which
proposed to the National Institutes of Health to analyze “time to
loading dose.” With respect to how data should be categorized, it is
perfectly acceptable to use statistical criteria (mean, median,
mode) to operationalize a hypothesis about early versus late initiation of treatment because the variable distribution is almost always
unknown before the trial is completed. This is particularly so when,
as in the NASCIS trials, there was no a priori biologic rationale for
defining a dichotomy. The whole hour close to the median (8.5
hours) was used because a more precise representation of time was
unwarranted as we only wished to classify “early” versus “late”
treatment. It is certainly an unacceptable analytic practice to analyze multiple cut-off points while presenting only the most favorable one; this was not done in the NASCIS.

These points are further supported by commentary in the
original NASCIS II NIH grant proposal and in more recent
Cochrane meta-analyses.30,31 While it remains unfortunate that
the rationale provided above was not included in the primary
NASCIS II manuscript, this justification should serve to establish the a priori nature of the “time to effect hypothesis,” and
disabuse individuals of the notion that the 8-hour cutoff was
chosen as a matter of convenience given the presence of a
positive effect.
In summary, when considering all studies included in our
meta-analysis, patients receiving MPSS within 8 hours of
injury had significantly larger motor gains at a minimum of
6 months follow-up, with treated patients experiencing an
additional 3.2 points of motor recovery (95% CI ¼ 0.10 to
6.3). When considering only randomized data, this margin
of benefit increased to an additional 3.8 points of motor
recovery (95% CI ¼ 0.50 to 7.27), with a “Moderate”
degree of confidence in this estimate. Although the magnitude of the effect observed is ostensibly small, the clinical
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Figure 5. Complications.

significance of such an improvement is unknown and likely
varies from patient to patient depending on the specifics of
the injury, including its severity and neurological level. Of
relevance, in a recent survey study, SCI patients were presented with an objective summary of the potential risks and
benefits of MPSS based on the trials discussed above.32

Overall, 41 of 69 respondents (59.4%) felt very strongly
that the motor and sensory benefits observed with the NASCIS II MPSS dose administered within 8 hours of injury
would be clinically important. Future work is needed to
improve the interpretability of neurological measures in the
context of SCI and to define what constitutes a clinically

Fehlings et al
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Figure 6. Timing of MPSS administration and motor scores.

Figure 7. Timing of MPSS administration and pinprick.

important change. It is, nonetheless, important to acknowledge that the statistically significant improvement in motor
function demonstrated by the most rigorously performed
clinical studies represents fewer than 5 motor points.
Appreciating the small magnitude of this improvement is
important for establishing realistic expectations about the
neuroprotective efficacy of MPSS in acute SCI.
In addition to including individual studies, we also considered previous systematic reviews in order to gauge how

other groups assessed the evidence on this topic. Across
the 7 systematic reviews that met our inclusion criteria,
conclusions and methodology varied substantially. With
respect to methodological quality, as evaluated by the
AMSTAR score, 3 reviews were rated as low quality,
3 were rated as medium quality, and 1 was rated as high
quality. Of note, the single review deemed to be high
quality (Cochrane meta-analysis authored by Bracken
et al) supported a positive impact of the 24-hour NASCIS
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Figure 8. Timing of MPSS administration and light touch.

Figure 9. Motor score in patients treated within 8 hours at final follow-up of 6-12 months.
*Evaniew had a median follow-up of 122 days

II MPSS regimen started within 8 hours of injury on longterm motor recovery, with overall results very similar to
those observed in this review.
Recently a systematic review and meta-analysis by Evaniew et al, published after our inclusion dates, sought to
determine the impact of MPSS on motor recovery and risk
of adverse events.33 This systematic review concluded, in
part, that the pooled evidence does not demonstrate a significant long-term benefit for MPSS in patients with acute
SCI. Furthermore, the authors conclude that their findings
support current guidelines against routine use; however,
they also note that strong recommendations are not warranted due to limited confidence in the effect estimate. Our
systematic review differs from theirs in 2 important areas.

First, we pooled studies into a final follow-up group with 6or 12-month follow-up, which included 3 studies: Otani et al
(6-month follow-up), Pointillart et al (12-month follow-up),
and Bracken et al (12-month follow-up). This seems reasonable given the profile of recovery for SCI patients, with the
bulk of improvement occurring in the first 6 to 9 months
postinjury. 34 On the other hand, Evaniew et al defined
6-month follow-up as short-term and therefore did not
include Otani et al in the long-term meta-analysis. As a
result, they report a nonsignificant result in long-term motor
improvement. Second, given that severity of injury has the
largest prognostic effect on SCI recovery and may influence
the decision on whether to administer MPSS, we only
included observational studies that controlled for this

Fehlings et al
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Table 5. Complications From the NASCIS III Trial Comparing 24-Hour Versus 48-Hour Infusion.
6-Week Complications

Urinary tract infection
Decubiti
Other infection
Phlebitis
Incision, pin, halo infection
Sepsis
Adult RDS
Atelectasis
Other respiratory failure
Pneumonia
GI hemorrhage
Thrombophlebitis
Pulmonary embolus
Bradycardia
Tachycardia
Other arrhythmia
Paralytic ileus
Other complications

Mild-moderate
Severe
Mild-moderate
Severe
Mild-moderate
Severe
Mild-moderate
Severe
Mild-moderate
Severe
Mild-moderate
Severe
Mild-moderate
Severe
Mild-moderate
Severe
Mild-moderate
Severe
Mild-moderate
Severe
Mild-moderate
Severe
Mild-moderate
Severe
Mild-moderate
Severe
Mild-moderate
Severe
Mild-moderate
Severe
Mild-moderate
Severe
Mild-moderate
Severe
Mild-moderate
Severe

Combined 6- and 12-Month Complications

24-Hour Infusion

48-Hour Infusion

24-Hour Infusion

48-Hour Infusion

34.4
0
12.3
0.6
3.9
0
2.6
0
1.9
0.6
3.9
0.6
1.9
1.3
5.2
0
7.8
1.9
12.3
2.6
0
0
2.6
0.6
0
1.3
2.6
1.3
0.6
0
0.6
0
1.3
0
11.7
4.5

38.3
0
13.6
0.6
7.8
0
1.3
0
2.6
1.9
4.5
2.6
1.9
1.9
7.1
0
9.1
3.2
11
5.8
1.3
0.6
4.5
0
0.6
0.6
0.6
0
2.6
0
1.9
0
3.2
0.6
18.2
5.8

53.1
0.8
13.8
3.4
4.1
0.7
0.7
0
1.4
0
0
0
0
0.7
1.4
0.7
1.4
0
2.8
1.4
0
0
2.1
1.4

49
3.3
13.4
6
4
0.7
0
0
0.7
0
1.3
1.3
0
0
0.7
0
0
0.7
3.4
1.4
0
0
2.7
0.7

Abbreviations: GI, gastrointestinal; RDS, respiratory distress syndrome.

potential confounder. Evaniew et al included observational
studies that did not control for severity. Given that patients
with a more severe injury may be more likely to receive
MPSS, the effect of MPSS on prognosis would be underestimated in these studies.

Study Limitations
Several limitations of this review must be recognized.
First, many of the included studies had methodological
shortcomings and risk of bias that resulted in the downgrading of the overall strength of evidence. As a result,
the overall strength of evidence was found to be moderate
for all 3 key questions. Second, although other studies
have evaluated other types of corticosteroids apart from
MPSS, as well as other dosing regimens of MPSS, these
were not included in this review; this decision was based

primarily on a desire to focus on studies comparing MPSS
to no treatment or placebo in order to obtain a better
estimate of the independent effects of this medication.
Last, when evaluating the impact of MPSS on certain subpopulations of patients, we chose to examine those receiving treatment within 8 hours of injury. Although this may
be somewhat arbitrary from a biological perspective, it
was chosen given the widespread adoption of this time
window by clinicians throughout the world following the
findings of the NASCIS II subanalysis. As a result, we felt
it necessary to critically evaluate the existing evidence
with respect to this time threshold.

Conclusions
When considering all time points of drug administration, there
is moderate evidence that the 24-hour NASCIS II MPSS
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regimen has no impact on indices of long-term neurological
recovery. However, there is moderate evidence of a small
improvement in motor recovery when the same regimen is
administered within 8 hours of injury. Although there is moderate evidence confirming the safety of the 24-hour regimen,
there may be a higher incidence of infectious complications
when the duration of infusion increases to 48 hours.
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